News | June 16, 2023
PrecisionLife announces strategic CNS drug development collaboration with Nanopharmaceutics
Collaboration to accelerate and de-risk clinical development of Nanopharmaceutics CNS portfolio
Collaboration to accelerate and de-risk clinical development of Nanopharmaceutics CNS portfolio
Total investments could reach €70 million, of which approximately 15% in R&D and 85% in capex, that would be deployed from 2026
Diclofenac Sodium and Misoprostol Delayed Release Tablets USP, 50mg/200 mcg and 75mg/200 mcg had annual sales of USD 13 mn in the United States
Samsung Biologics will provide Pfizer with additional capacity for large-scale manufacturing for a multi-product biosimilars portfolio
UTD2 is the world's first oral epothilone microtubule inhibitor
Chinook Therapeutics is a clinical-stage biopharmaceutical company with two high-value, late-stage assets in development for IgA nephropathy (IgAN), a rare, progressive chronic kidney disease
The new API plant is set up to meet all domestic and international regulatory standards and will manufacture niche molecules that have a global requirement
The EU certification will support supplies of drug products registered in Europe, from this manufacturing site
The primary endpoint is to measure the change in liver stiffness measurement performed by transient elastography from Baseline to Week 52
Acquisition accelerates Cosette’s women’s health portfolio; with a differentiated, commercial stage, patent protected product
Subscribe To Our Newsletter & Stay Updated
